TAKARA BIO INC.

4974 タカラバイオ株式会社

Biotechnology · Prime · TSE: Disclosed

PRICE: ¥1,144 · MKT CAP: ¥137.8B · P/E: 132.3x · P/B: 1.19x · DIV YIELD: 1.5%

PRICE — 5Y

Characteristics & Business Summary

Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and...

Income Statement Highlights (¥ Million, except EPS/DPS in ¥)

Fiscal Period	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Net Sales	46,086	67,699	78,142	43,505	45,039
Operating Profit	13,952	28,902	20,541	3,003	2,263
Ordinary Profit	14,159	28,459	20,682	3,405	2,592
Net Profit	9,547	19,849	16,012	1,480	1,041
EPS	¥79	¥165	¥133	¥12	¥9
DPS	¥16	¥33	¥42	¥17	¥17

Balance Sheet & Valuation Highlights

Total Assets ¥125B

Net Assets (Equity) ¥116B

Equity Ratio 92.2%

ROE (Return on Equity) 1.0%

Cash & Equivalents ¥30B

Interest-Bearing Debt ¥0B

Capital Expenditure (CapEx) ¥0B

Depreciation & Amort. ¥4B

Major Shareholders

1. 宝ホールディングス株式会社 60.9%
2. The Master Trust Bank of Japan, Ltd. (Trust Account) 6.4%
3. Custody Bank of Japan, Ltd. (Trust Account) 1.7%
4. State Street Bank and Trust Company 0.7%
5. SIX SIS AG FOR CAP VIVA-AKTIEN AUSLAND（常任代理人株式会社三菱UFJ銀行） 0.6%
6. JPMorgan Chase Bank, N.A. 0.6%
7. State Street Bank and Trust Company 0.5%
8. 株式会社京都銀行 0.4%
9. 天野博夫 0.4%
10. タカラバイオ従業員持株会 0.4%

Activist Activity

Nomura Asset Management Co., Ltd. 1.99%

2026-04-21 · change

TAKARA HOLDINGS INC. 87.27%

2026-04-09 · change

Nomura Asset Management Co., Ltd. 5.32%

2026-03-19 · initial_5pct

Historical Per-Share Data & Valuation Ratios

Per Share Metric	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Revenues per share	¥383	¥562	¥649	¥361	¥374
FCF/Share	¥116	¥58	¥306	¥14	¥49
EPS	¥79	¥165	¥133	¥12	¥9
DPS	¥16	¥33	¥42	¥17	¥17
Capital Spending per share	¥0	¥0	¥0	¥0	¥0
Book Value per share	¥622	¥771	¥871	¥842	¥833
Common Shares Outstanding	120M	120M	120M	120M	120M

Financial Aggregates & Margins

Financial Aggregate	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Revenues (Net Sales)	¥46B	¥68B	¥78B	¥44B	¥45B
Operating Margin (%)	30.3%	42.7%	26.3%	6.9%	5.0%
Net Profit (owners)	¥10B	¥20B	¥16B	¥1B	¥1B
Net Profit Margin (%)	20.7%	29.3%	20.5%	3.4%	2.3%
Working Capital	¥34B	¥48B	¥61B	¥53B	¥48B
Total Debt (Interest-bearing)	¥0B	¥0B	¥0B	¥0B	¥0B
Net Worth (Common Equity)	¥75B	¥93B	¥105B	¥101B	¥100B
Return on Total Assets (ROA)	10.6%	17.2%	12.4%	1.2%	0.8%
Return on Common Equity (ROE)	12.7%	21.4%	15.3%	1.5%	1.0%

Business Summary & Analysis

Capital Strategy Targets

No active capital policy disclosure records found.